Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

NASDAQ:VRDN - US92790C1045 - Common Stock

18.8 USD
+0.23 (+1.24%)
Last: 8/26/2025, 1:49:07 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VRDN. VRDN was compared to 547 industry peers in the Biotechnology industry. VRDN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRDN has reported negative net income.
In the past year VRDN has reported a negative cash flow from operations.
VRDN had negative earnings in each of the past 5 years.
In the past 5 years VRDN always reported negative operating cash flow.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

VRDN has a Return On Assets (-59.08%) which is comparable to the rest of the industry.
VRDN's Return On Equity of -66.79% is in line compared to the rest of the industry. VRDN outperforms 58.14% of its industry peers.
Industry RankSector Rank
ROA -59.08%
ROE -66.79%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
The debt/assets ratio for VRDN has been reduced compared to a year ago.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 9.68 indicates that VRDN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.68, VRDN belongs to the top of the industry, outperforming 85.74% of the companies in the same industry.
VRDN has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
VRDN's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. VRDN outperforms 41.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 9.68
ROIC/WACCN/A
WACC9.74%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 11.01. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN has a better Current ratio (11.01) than 82.82% of its industry peers.
VRDN has a Quick Ratio of 11.01. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.01, VRDN belongs to the top of the industry, outperforming 82.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.01
Quick Ratio 11.01
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.41% over the past year.
Looking at the last year, VRDN shows a small growth in Revenue. The Revenue has grown by 6.64% in the last year.
The Revenue for VRDN have been decreasing by -41.64% on average. This is quite bad
EPS 1Y (TTM)5.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)6.64%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%4.17%

3.2 Future

VRDN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.18% yearly.
The Revenue is expected to grow by 401.65% on average over the next years. This is a very strong growth
EPS Next Y1.54%
EPS Next 2Y-3.16%
EPS Next 3Y14.85%
EPS Next 5Y22.18%
Revenue Next Year-54.94%
Revenue Next 2Y1159.28%
Revenue Next 3Y867.69%
Revenue Next 5Y401.65%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

VRDN's earnings are expected to grow with 14.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.16%
EPS Next 3Y14.85%

More info and screens

0

5. Dividend

5.1 Amount

VRDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (8/26/2025, 1:49:07 PM)

18.8

+0.23 (+1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners113.92%
Inst Owner Change2.8%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.54B
Analysts84.55
Price Target39.72 (111.28%)
Short Float %14.32%
Short Ratio15.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.34%
Min EPS beat(2)2.88%
Max EPS beat(2)11.8%
EPS beat(4)3
Avg EPS beat(4)3.35%
Min EPS beat(4)-6.6%
Max EPS beat(4)11.8%
EPS beat(8)5
Avg EPS beat(8)1.79%
EPS beat(12)7
Avg EPS beat(12)-5.98%
EPS beat(16)9
Avg EPS beat(16)-6.46%
Revenue beat(2)2
Avg Revenue beat(2)34.57%
Min Revenue beat(2)0.65%
Max Revenue beat(2)68.49%
Revenue beat(4)4
Avg Revenue beat(4)53%
Min Revenue beat(4)0.65%
Max Revenue beat(4)84.21%
Revenue beat(8)4
Avg Revenue beat(8)12.64%
Revenue beat(12)5
Avg Revenue beat(12)18.46%
Revenue beat(16)6
Avg Revenue beat(16)7.49%
PT rev (1m)-1.11%
PT rev (3m)-4.45%
EPS NQ rev (1m)12.44%
EPS NQ rev (3m)18.38%
EPS NY rev (1m)3.29%
EPS NY rev (3m)3.49%
Revenue NQ rev (1m)13.24%
Revenue NQ rev (3m)-25.87%
Revenue NY rev (1m)-28.29%
Revenue NY rev (3m)-22.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5033.47
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)-4.02
EYN/A
EPS(NY)-4.21
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.78
OCFYN/A
SpS0
BVpS6.31
TBVpS6.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.08%
ROE -66.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.77%
Cap/Sales 175.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.01
Quick Ratio 11.01
Altman-Z 9.68
F-Score3
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y1.54%
EPS Next 2Y-3.16%
EPS Next 3Y14.85%
EPS Next 5Y22.18%
Revenue 1Y (TTM)6.64%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%4.17%
Revenue Next Year-54.94%
Revenue Next 2Y1159.28%
Revenue Next 3Y867.69%
Revenue Next 5Y401.65%
EBIT growth 1Y-48.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.93%
EBIT Next 3Y11.83%
EBIT Next 5Y36.92%
FCF growth 1Y-90.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.9%
OCF growth 3YN/A
OCF growth 5YN/A